Trial Profile
A phase ll study of combination therapy with Panitumumab plus CPT-11 for advanced and/or recurrent colon-rectal cancer with wild type KRAS which has prior therapy of fluoropylimidine, oxaliplatin or CPT-11.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2018
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 25 Jun 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 24 Jul 2012 Planned end date changed from 1 Jul 2012 to 31 Jul 2013 as reported by University Hospital Medical Information Network - Japan record.
- 24 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.